Kamada Ltd. (KMDA)
USD 5.76
(-1.37%)
USD 5.76
(-1.37%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 109.96 Million USD | -24.86% |
| 2022 | 146.35 Million USD | 3.18% |
| 2021 | 141.84 Million USD | 342.89% |
| 2020 | 32.02 Million USD | -16.77% |
| 2019 | 38.47 Million USD | 49.49% |
| 2018 | 25.74 Million USD | -21.09% |
| 2017 | 32.61 Million USD | -1.02% |
| 2016 | 32.95 Million USD | 11.76% |
| 2015 | 29.48 Million USD | -23.66% |
| 2014 | 38.62 Million USD | -21.83% |
| 2013 | 49.4 Million USD | -18.63% |
| 2012 | 60.72 Million USD | -3.27% |
| 2011 | 62.77 Million USD | -3.47% |
| 2010 | 65.03 Million USD | 98.51% |
| 2009 | 32.76 Million USD | 11.36% |
| 2008 | 29.41 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 95.78 Million USD | -12.9% |
| 2024 Q2 | 99.57 Million USD | 3.95% |
| 2023 Q2 | 137.63 Million USD | -3.06% |
| 2023 FY | 109.96 Million USD | -24.86% |
| 2023 Q4 | 109.96 Million USD | 11.46% |
| 2023 Q1 | 141.98 Million USD | -2.99% |
| 2023 Q3 | 98.66 Million USD | -28.31% |
| 2022 Q3 | 147.08 Million USD | 10.96% |
| 2022 Q1 | 127.94 Million USD | -9.8% |
| 2022 Q2 | 132.56 Million USD | 3.61% |
| 2022 FY | 146.35 Million USD | 3.18% |
| 2022 Q4 | 146.35 Million USD | -0.49% |
| 2021 Q3 | 34.91 Million USD | 2.67% |
| 2021 Q1 | 29.3 Million USD | -8.49% |
| 2021 FY | 141.84 Million USD | 342.89% |
| 2021 Q2 | 34 Million USD | 16.03% |
| 2021 Q4 | 141.84 Million USD | 306.26% |
| 2020 Q3 | 29.61 Million USD | -18.47% |
| 2020 Q2 | 36.32 Million USD | 17.26% |
| 2020 Q1 | 30.97 Million USD | -19.49% |
| 2020 Q4 | 32.02 Million USD | 8.14% |
| 2020 FY | 32.02 Million USD | -16.77% |
| 2019 FY | 38.47 Million USD | 49.49% |
| 2019 Q1 | 27.62 Million USD | 7.33% |
| 2019 Q2 | 32.48 Million USD | 17.59% |
| 2019 Q3 | 26.36 Million USD | -18.86% |
| 2019 Q4 | 38.47 Million USD | 45.97% |
| 2018 Q4 | 25.74 Million USD | 21.39% |
| 2018 FY | 25.74 Million USD | -21.09% |
| 2018 Q3 | 21.2 Million USD | -23.71% |
| 2018 Q2 | 27.79 Million USD | -8.65% |
| 2018 Q1 | 30.42 Million USD | -6.72% |
| 2017 Q3 | 28.27 Million USD | -11.23% |
| 2017 Q2 | 31.85 Million USD | 6.51% |
| 2017 Q1 | 29.91 Million USD | -9.23% |
| 2017 FY | 32.61 Million USD | -1.02% |
| 2017 Q4 | 32.61 Million USD | 15.34% |
| 2016 Q2 | 29.18 Million USD | -18.41% |
| 2016 Q3 | 25.92 Million USD | -11.16% |
| 2016 Q4 | 32.95 Million USD | 27.1% |
| 2016 Q1 | 35.77 Million USD | 21.32% |
| 2016 FY | 32.95 Million USD | 11.76% |
| 2015 Q4 | 29.48 Million USD | -20.98% |
| 2015 Q1 | 34.77 Million USD | -9.97% |
| 2015 Q2 | 35.49 Million USD | 2.07% |
| 2015 FY | 29.48 Million USD | -23.66% |
| 2015 Q3 | 37.31 Million USD | 5.12% |
| 2014 Q3 | 47.64 Million USD | -5.2% |
| 2014 Q1 | 50.35 Million USD | 1.9% |
| 2014 Q2 | 50.25 Million USD | -0.19% |
| 2014 FY | 38.62 Million USD | -21.83% |
| 2014 Q4 | 38.62 Million USD | -18.93% |
| 2013 FY | 49.4 Million USD | -18.63% |
| 2013 Q3 | 57.7 Million USD | -3.11% |
| 2013 Q2 | 59.55 Million USD | -3.67% |
| 2013 Q1 | 61.82 Million USD | 1.82% |
| 2013 Q4 | 49.4 Million USD | -14.38% |
| 2012 FY | 60.72 Million USD | -3.27% |
| 2012 Q3 | 61.75 Million USD | 0.0% |
| 2012 Q4 | 60.72 Million USD | -1.68% |
| 2011 FY | 62.77 Million USD | -3.47% |
| 2010 FY | 65.03 Million USD | 98.51% |
| 2009 FY | 32.76 Million USD | 11.36% |
| 2008 FY | 29.41 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Journey Medical Corporation | 56.49 Million USD | -94.638% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 76.685% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | 32.907% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 84.385% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -1691.131% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -1691.131% |
| SCYNEXIS, Inc. | 55.45 Million USD | -98.32% |
| Safety Shot Inc | 3.89 Million USD | -2725.464% |
| Alpha Teknova, Inc. | 38.55 Million USD | -185.254% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 88.398% |
| Bright Green Corporation | 6.43 Million USD | -1608.086% |
| Dynavax Technologies Corporation | 375.02 Million USD | 70.677% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 83.358% |
| Cosmos Health Inc. | 30.25 Million USD | -263.501% |
| PainReform Ltd. | 2.69 Million USD | -3986.521% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -1095.748% |
| Embecta Corp. | 2.03 Billion USD | 94.599% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | 19.656% |
| Procaps Group, S.A. | 462.06 Million USD | 76.201% |
| Theratechnologies Inc. | 98.63 Million USD | -11.486% |
| Harrow Health, Inc. | 241.75 Million USD | 54.512% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -1155.919% |
| Biofrontera Inc. | 23.13 Million USD | -375.251% |
| DURECT Corporation | 30.4 Million USD | -261.666% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 77.441% |
| Cronos Group Inc. | 43.73 Million USD | -151.436% |
| OptiNose, Inc. | 194.33 Million USD | 43.413% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 86.546% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -126.996% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -424.205% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 39.365% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -2815.281% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | -109.399% |
| Radius Health, Inc. | 804.29 Million USD | 86.327% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -699.518% |
| ProPhase Labs, Inc. | 42.54 Million USD | -158.481% |
| Phibro Animal Health Corporation | 725.54 Million USD | 84.843% |
| Procaps Group S.A. | 462.06 Million USD | 76.201% |
| Alvotech | 1.88 Billion USD | 94.159% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -684.255% |
| Viatris Inc. | 27.21 Billion USD | 99.596% |
| Rockwell Medical, Inc. | 30.88 Million USD | -256.092% |
| Aytu BioPharma, Inc. | 90.37 Million USD | -21.675% |
| SIGA Technologies, Inc. | 57.97 Million USD | -89.675% |
| Tilray Brands, Inc. | 892.11 Million USD | 87.673% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 49.969% |
| Shineco, Inc. | 47.6 Million USD | -131.018% |
| PetIQ, Inc. | 645.22 Million USD | 82.957% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -49996.711% |
| Incannex Healthcare Limited | 5.83 Million USD | -1786.249% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 89.212% |
| Alimera Sciences, Inc. | 107.35 Million USD | -2.435% |
| Silver Spike Investment Corp. | 3 Million USD | -3553.637% |
| Assertio Holdings, Inc. | 148.41 Million USD | 25.905% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -5700.122% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -415.901% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -1465.162% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -1195.187% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | 36.576% |
| Hempacco Co., Inc. | 18.82 Million USD | -484.241% |
| Talphera, Inc. | 6.29 Million USD | -1648.304% |
| Alvotech | 1.88 Billion USD | 94.159% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | 36.287% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 86.834% |
| Currenc Group, Inc. | 177.67 Million USD | 38.107% |
| Indivior PLC | 1.95 Billion USD | 94.364% |
| Evoke Pharma, Inc. | 9.64 Million USD | -1039.794% |
| Flora Growth Corp. | 17.22 Million USD | -538.534% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -1195.187% |
| Evolus, Inc. | 209.68 Million USD | 47.556% |
| HUTCHMED (China) Limited | 536.38 Million USD | 79.498% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 87.41% |
| Akanda Corp. | 12.66 Million USD | -768.019% |